Improved Prognostic Testing for Patients with Triple Negative Breast Cancer
Approximately 40% of patients with stage I-III triple-negative breast cancer (TNBC) have recurrences after standard treatment, whereas the remaining 60% experience long-term disease-free survival. However, there are currently no clinical tests to assess the risk of recurrence in TNBC patients. Continue reading → Improved Prognostic Testing for Patients with Triple Negative Breast Cancer